Catalyst Private Wealth’s Rapport Therapeutics RAPP Stock Holding History

Catalyst Private Wealth’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$338K	Buy	10,046 +46	+0.5%	+$1.99K	0.14%	71
2026 Q2	$417K	Hold	10,000	–	–	0.2%	56
2026 Q1	$313K	Hold	10,000	–	–	0.17%	60
2025 Q4	$303K	Hold	10,000	–	–	0.13%	65
2025 Q3	$297K	Hold	10,000	–	–	0.13%	67
2025 Q2	$114K	Hold	10,000	–	–	0.05%	78
2025 Q1	$100K	Buy	+10,000	New	+$130K	0.05%	77

Other funds holding RAPP

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Catalyst Private Wealth's RAPP Position: Q3 2026 in Review

Catalyst Private Wealth increased its Rapport Therapeutics (RAPP) stake by 0.46% in Q3 2026, buying an estimated $1.99K and bringing the position to 10,046 shares worth $338K. The position accounts for 0.14% of the portfolio, ranked #71.

Catalyst Private Wealth first reported a position in RAPP in Q1 2025 and has held it in 7 quarters since. The position peaked at $417K in Q2 2026. 31 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

Catalyst Private Wealth held 10,046 shares of Rapport Therapeutics worth $338K as of Q3 2026.
Catalyst Private Wealth bought 46 Rapport Therapeutics shares in Q3 2026, an estimated $1.99K.
Rapport Therapeutics made up 0.14% of Catalyst Private Wealth's portfolio in Q3 2026, its #71 holding.
Catalyst Private Wealth first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 7 quarters since.
Catalyst Private Wealth's Rapport Therapeutics position peaked at $417K in Q2 2026.
31 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Catalyst Private Wealth's 13F filing for Q3 2026, filed 13 Oct 2026.